Does paraoxonase play a role in susceptibility to cardiovascular disease?

Molecular Medicine Today

Volumn 5, Issue 9, 1999, Pages 381-386

  Aviram, Michael ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOENZYME; ARYLDIALKYLPHOSPHATASE; FLAVONOID; GLABRIDIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; DISEASE MARKER; DISEASE PREDISPOSITION; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; GENETIC POLYMORPHISM; HEART PROTECTION; HUMAN; NONHUMAN; REVIEW; RISK FACTOR;

EID: 0032784986     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01546-4     Document Type: Note

References (34)

1. Steinberg D.et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. New Engl. J. Med. 320:1989;915-924.
2. Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis and the antiatherogenicity of antioxidants. Eur. J. Clin. Chem. Clin. Biochem. 34:1996;599-608.
3. Aviram M., Fuhrman B. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Mol. Cell. Biochem. 188:1998;149-159.
4. Aviram M. Antioxidants in restenosis and atherosclerosis. Current interventional. Cardiol. Rep. 1:1999;66-78.
5. Fuhrman B.et al. Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. Free Radic. Biol. Med. 23:1997;34-46.
6. Oram J.F. Receptor-mediated transport of cholesterol between cultured cells and high density lipoproteins. Methods Enzymol. 129:1986;645-659.
7. Mackness M.I.et al. Paraoxonase and coronary heart disease. Curr. Opin. Lipidology. 9:1998;319-324.
8. Davies H.G.et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14:1996;334-336.
9. La Du B.N. Structural and functional diversity of paraoxonases. Nat. Med. 2:1996;1186-1187.
10. Aviram M.et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101:1998;1581-1590.
11. Heinecke J.W., Lusis A.J. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am. J. Hum. Genet. 62:1998;20-24.
12. Mackness B., Hunt R., Durrington P.N., Mackness M.I. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;1233-1238.
13. Shih D.M.et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1996;1630-1639.
14. Shih D.M.et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394:1998;284-287.
15. Zama T.et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler. Thromb. Vasc. Biol. 17:1997;3565-3569.
16. Pati N., Pati U. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int. J. Cardiol. 30:1998;165-168.
17. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;1067-1073.
18. Ruiz J.et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
19. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;2257-2260.
20. Ko Y.L.et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis. 141:1998;259-264.
21. Cao H.et al. Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis. 138:1998;361-366.
22. Antikainen M.et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98:1996;883-885.
23. Ombres D.et al. The Gln-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler. Thromb. Vasc. Biol. 18:1998;1611-1616.
24. Rice G.I., Ossei-Gerning N., Stickland M.H., Grant P.J. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron. Artery Dis. 8:1997;677-682.
25. Herrmann S.M. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 126:1996;299-303.
26. Garin M.C.et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99:1997;62-66.
27. Sanghera D.K.et al. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis. 136:1998;217-223.
28. Hegele R.A.et al. Paraoxonase-2 gene (PON 2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;3373-3377.
29. Aviram M.et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different than that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18:1998;1617-1624.
30. Sorenson, R.C. et al. The association of human serum paraoxonase/arylesterase with high density lipoprotein is mediated through the binding of its retained hydrophobic N-terminal leader sequence to phospholipid and does not require a direct association with apolipoprotein A-I, Arterioscler. Thromb. Vasc. Biol. (in press).
31. Watson A.D.et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96:1995;2882-2891.
32. Navab M.et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff memorial lecture. Arterioscler. Thromb. Vasc. Biol. 16:1996;831-842.
33. Aviram M.et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26:1999;892-904.
34. Hayek T.et al. Reduced progression of atherosclerosis in the apolipoprotein E deficient mice following consumption of red wine, or its polyphenols quercetin, or catechin, is associated with reduced susceptibility of LDL to oxidation and to aggregation. Arterioscl. Thromb. Vasc. Biol. 17:1997;2744-2752.